Rentschler Biopharma to Construct New Buffer Media Facility in Germany

Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, is building a new state-of-the-art buffer media station at its company headquarters in Laupheim, Germany.¹ According to the company, the new plant is expected to boost production efficiency, while adding a modern feel to the facility, which will be critical to addressing client and patient needs.

“This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries,” said Benedikt von Braunmühl, CEO of Rentschler Biopharma. “As a company with 150 years of tradition, Rentschler Biopharma has always embraced forward-looking, strategic planning, enabling us to grow sustainably as an independent family-owned company. I would like to thank all colleagues involved in the planning and execution of this significant project. Government support for a German national pharmaceutical strategy is an important signal for the industry as a whole. While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy.”

Building construction is expected to commence in spring 2025. While completion and operational launch is set for the end 2027, the new 360,000 square-foot, four-story buffer media station itself is projected to be ready 2028.It is expected to meet the various quality and automation standards, while supporting Rentschler Biopharma's environmental and sustainability goals. The new site will also feature three media tanks and six buffer tanks, which is expected to be enough space for the production of buffer solutions and media.

“As a CDMO, it is our responsibility to support our clients in transforming innovative ideas into life-saving biopharmaceuticals. Patients with rare and severe diseases rely on the therapies we develop and manufacture in partnership with our clients,” noted Christiane Bardroff, Rentschler Biopharma’s COO. “This project is therefore not just an investment in our infrastructure, it is a fundamental part of our work, creating value sustainably for the benefit of our clients and for patients and ensuring the availability of therapeutics in Germany and globally. With the new buffer media station, we are making a significant contribution to operational excellence, enabling us to respond rapidly to growing client demands. We are also creating a more ergonomic work environment for our employees and positioning our site for future success.”

References

1. Rentschler Biopharma Announces Largest Single Investment at Its Headquarters in Germany. Rentschler Biopharma. October 24, 2024. Accessed October 28, 2024. https://www.rentschler-biopharma.com/en-us/news-events/press-releases/rentschler-biopharma-announces-largest-single-investment-at-headquarters-in-germany/